Alberto Ortega

Prof. Alberto Ortega

Hospital Universitario La Fe, Valencia
+1
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Journal of Infection
Verified
Journal Article
Closed access
AOAlberto Ortega
Alberto Ortega
GOGrace Oscullo
Grace Oscullo
PCPilar Calvillo
Pilar Calvillo
RLRaquel López-Reyes
Raquel López-Reyes
RMRaúl Méndez
Raúl Méndez
MMMiguel Ángel Martínez-García
Miguel Ángel Martínez-García

17 February 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
TBTomas J Posadas Blázquez
Tomas J Posadas Blázquez
GYGrace Jacqueline Oscullo Yepez
Grace Jacqueline Oscullo Yepez
EZEnrique Zaldívar
Enrique Zaldívar
AOAlberto Ortega
Alberto Ortega
JGJosé Daniel Gómez-Olivas
José Daniel Gómez-Olivas
MMMiguel Angel Martinez-Garcia
Miguel Angel Martinez-Garcia
The population pyramid is changing as a result of the ever-increasing life expectancy, which makes it crucial to acquire an in-depth understanding of the diseases that most often affect the elderly. Obstructive sleep apnoea (OSA) affects 15%–20% of the population aged over 65 years. Despite this prevalence, there have been very few specific studies on the management of OSA in this age group, even though over 60% of the patients aged over 65-70 years who attend sleep units with suspicion of OSA receive treatment with continuous positive airway pressure (CPAP), on the basis of an extrapolation of the positive results achieved by CPAP in clinical trials involving middle-aged males. However, the latter’s form of presentation, evolution and, probably, prognosis comparing with OSA are not the same as those of elderly patients. Recent clinical trials performed on an exclusive series of elderly patients have shed light on the possible role of CPAP treatment in elderly patients with OSA, but there are still many questions that need to be answered. The physiological increase in the number of sleep-related disorders with the passing of years, and the lack of validated diagnostic and therapeutic tools for this age group are probably the greatest obstacles to define, diagnose and treat OSA in the elderly.

1 January 2022 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Open access
FSFakiha Siddiqui
Fakiha Siddiqui
AOAlberto Ortega
Alberto Ortega
BKBulent Kantarcioglu
Bulent Kantarcioglu
JSJames Sinacore
James Sinacore
ATAlfonso Tafur
Alfonso Tafur
TIthe RIETE investigators
the RIETE investigators
Background: Cellular indices provide integrative information about systemic inflammation status which is readily available from routine laboratory parameters. This study aimed to evaluate the prognostic role of three cellular indices in patients with venous thromboembolism (VTE). Methods: The RIETE registry database was used to determine the association between the baseline neutrophil-to-lymphocyte-ratio (NLR), platelet-to-lymphocyte-ratio (PLR) and systemic-immune-inflammation-index (SII) for 90-day adverse outcomes in patients with acute VTE. Results: From January 2020 to April 2021, 4487 patients with acute VTE were recruited in the RIETE registry. Of these, 2683 presented with symptomatic pulmonary embolism (PE); 283 with incidental PE; 1129 with lower-limb deep vein thrombosis (DVT); 175 with upper-limb DVT; 69 with splanchnic vein thrombosis; 142 with superficial vein thrombosis and 20 with retinal vein thrombosis. Mean values were: NLR 5.9 ± 7.1, PLR 190 ± 158 and SII 1459 ± 2028. During the first 90-days, 38 patients (0.8%) developed recurrent DVT, 45 (1.0%) had recurrent PE, 152 (3.4%) suffered major bleeding, and 484 (11%) died. On multivariable analysis, patients with NLR >4.41 were at an increased risk for major bleeding and patients with NLR >4.96 were at the risk of death, while those with SII >1134.5 were at increased risk for death. Conclusions: This study reports the results of a large cohort to date which evaluate the prognostic value of three cellular indices simultaneously in patients with acute VTE. Results support that none of the three baseline cellular indices were sufficient for prediction of VTE recurrences in acute VTE patients. The patients with higher baseline NLR values were at an increased risk of major bleeding or death, those with high SII values were only at an increased risk for mortality.

1 February 2021 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
AOAlberto Ortega
Alberto Ortega
DRDavid de la Rosa
David de la Rosa
GOGrace Oscullo
Grace Oscullo
DCDiego Castillo-Villegas
Diego Castillo-Villegas
RLRaquel LópEz-Reyes
Raquel LópEz-Reyes
MMMiguel ÁnGel MartínEz-García
Miguel ÁnGel MartínEz-García
The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been an unprecedented global health problem, causing more than 20 million infections and more than 900,000 deaths (September 2020). The SARS-CoV-2 infection, known as COVID-19, has various clinical presentations, from asymptomatic or mild catarrhal processes to severe pneumonia that rapidly progresses to acute respiratory distress syndrome (ARDS) and multiple organ failure. In the last few months, much scientific literature has been devoted to descriptions of different aspects of the coagulation disorders and arterial and venous thrombotic complications associated with COVID-19, particularly venous thromboembolism (VTE). These studies have revealed that SARS-CoV-2 could lead to a prothrombotic state reflecting the high cumulative incidence of associated thrombotic events, particularly in patients admitted to intensive care units (ICUs). As regards the coagulopathy observed in association with SARS-CoV-2 infection, the mechanisms that activate coagulation have been hypothesized as being linked to immune responses, through the release of pro-inflammatory mediators that interact with platelets, stimulate the expression of tissue factor, induce an upregulation of plasminogen activator inhibitor-1, suppress the fibrinolytic system and lead to endothelial dysfunction, triggering thrombogenesis. D-dimer elevation has been recognized as a useful biomarker of poor prognosis, although the best cut-off point for predicting VTE in COVID-19 patients has still not been clarified. This review will try to update all the available scientific information on this important topic with enormous clinical and therapeutic implications.

1 May 2021 in Thrombosis Research
Verified
Journal Article
Closed access
AOAlberto Ortega
Alberto Ortega
RLRaquel López-Reyes
Raquel López-Reyes
GAGabriel Anguera
Gabriel Anguera
GOGrace Oscullo
Grace Oscullo
ARAgustina Rivas
Agustina Rivas
MMManuel Monreal
Manuel Monreal

4 January 2024 in Archivos de Bronconeumología
Verified
Journal Article
Closed access
AOAlberto Ortega
Alberto Ortega
DJDavid Jiménez
David Jiménez
APAna Pedro-Tudela
Ana Pedro-Tudela
CPCristina Pérez-Ductor
Cristina Pérez-Ductor
CFCarmen Fernández-Capitán
Carmen Fernández-Capitán
RIRIETE investigators
RIETE investigators